Carazolol
Clinical data | |
---|---|
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C18H22N2O3 |
Molar mass | 298.38 |
WikiDoc Resources for Carazolol |
Articles |
---|
Most recent articles on Carazolol |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Carazolol at Clinical Trials.gov Clinical Trials on Carazolol at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Carazolol
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Carazolol Discussion groups on Carazolol Directions to Hospitals Treating Carazolol Risk calculators and risk factors for Carazolol
|
Healthcare Provider Resources |
Causes & Risk Factors for Carazolol |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Carazolol is a high affinity antagonist/partial inverse agonist (also referred to as a beta blocker) of the β-adrenergic receptor.[1]
External links
- Carazolol at the US National Library of Medicine Medical Subject Headings (MeSH)
References
- Pages with script errors
- CS1 maint: Multiple names: authors list
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Cardiovascular Drugs
- Drug
- Beta blockers